D609

CAS No. 83373-60-8

D609( —— )

Catalog No. M33331 CAS No. 83373-60-8

D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 50 Get Quote
10MG 79 Get Quote
25MG 124 Get Quote
50MG 181 Get Quote
100MG 260 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    D609
  • Note
    Research use only, not for human use.
  • Brief Description
    D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.
  • Description
    D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a Ki of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity.
  • In Vitro
    Cell Proliferation AssayCell Line:RAW 264.7 macrophages, N9 and BV-2 microglia, and DITNC1 astrocytes,Concentration:100 μM Incubation Time:For 2 hoursResult:Significantly attenuated the proliferation of RAW 264.7 macrophages, N9 and BV-2 microglia, and DITNC1 astrocytes, without affecting cell viability.Apoptosis Analysis Cell Line:BV-2 cells Concentration:50, 100 and 200 μM Incubation Time:For 2 hours Result:Activated caspase-3 in a dose- and time-dependent manner. Cell Cycle Analysis Cell Line:BV-2 cells Concentration:100 μM Incubation Time:For 2 hours Result:Significantly inhibited BrdU incorporation in BV-2 microglia and caused accumulation of cells in G1 phase with decreased number of cells in the S phase.Western Blot Analysis Cell Line:BV-2 cells Concentration:100 μM Incubation Time:For 2 hours Result:Increased ceramide levels, up-regulated p21 expression and causes a decreased in phospho-Rb.
  • In Vivo
    Animal Model:26-week-old apoE?/? and C57BL/6 WT mice Dosage:2.5, 10 mg/kg Administration:IP; per day for 6 weeks Result:Inhibited the progression of preexisting atherosclerotic lesions in apoE?/? mice and changed the lesion composition into a more stable phenotype. Significantly decreased the aortic endothelial expression of the vascular cell adhesion molecule-1 and the intercellular adhesion molecule-1.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | Antioxidant
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    83373-60-8
  • Formula Weight
    266.46
  • Molecular Formula
    C11H15KOS2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (375.29 mM; Ultrasonic ) H2O : 2 mg/mL (7.51 mM; Ultrasonic)
  • SMILES
    SC(=S)OC1CC2CC1C1CCCC21
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. E Amtmann, et al. The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res. 1996;22(6):287-94.?
molnova catalog
related products
  • β-Elemene

    β-Elemene is a natural product isolated from Curcuma wenyujin, with an antitumor activity and induce cell apoptosis.β-Elemene significantly inhibited the metastatic capacity of MDR gastric cells in vivo and in vitro.?Mechanistically, β-Elemene regulated MMP-2/9 expression and reversed epithelial-mesenchymal transition.?

  • Se-Aspirin

    Se-Aspirin (Se-NSAID-8) has anticancer activity and gastroprotective effects, inhibits activation of proinflammatory and pro-survival NF-?B pathways, and inhibits the expression of anti-apoptotic targets downstream of NF-?B (e.g., Bcl-xL, Mcl-1, and survivin).

  • RH1

    RH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.